Probiotic supplementation in pregnant women with intrauterine growth restriction

Growing response to probiotic supplementation in pregnant women with intrauterine growth restriction

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140525017827N13

Enrollment

Registered

2021-11-20

Start date

2021-11-22

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine growth restriction. Intrauterine growth restriction

Interventions

Intervention 1: Intervention group: 25 of participant were treated with probiotic supplements of probiotic bacteria in the present study, including: Lactobacillus acidophilus 2CFU, Bifidobacterium bif

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Age 18 to 40 years Women's BMI should be in the range 19.5-29.9 Gravid 1 Mean UAPI in the study group > 2.53 Gestational age 11 to 13 weeks and six days uterine vascular resistance is high

Exclusion criteria

Exclusion criteria: Liver and kidney disease Thyroid disorders Complete bed rest

Design outcomes

Primary

Measure	Time frame
Total plasma antioxidant capacity (TAC). Timepoint: before starting medications and at 28 weeks. Method of measurement: Benzie and Strain methods by calorimetric method using Cusabio Biotech Co.;Plasma Glutathione (GPX) Activity. Timepoint: Before starting medications and at 28 weeks. Method of measurement: Beutler method using Cusabio Biotech Co.;Malondialdehyde (MDA). Timepoint: Before starting medications and at 28 weeks. Method of measurement: TBARS method.	—

Measure

Time frame

Total plasma antioxidant capacity (TAC). Timepoint: before starting medications and at 28 weeks. Method of measurement: Benzie and Strain methods by calorimetric method using Cusabio Biotech Co.;Plasma Glutathione (GPX) Activity. Timepoint: Before starting medications and at 28 weeks. Method of measurement: Beutler method using Cusabio Biotech Co.;Malondialdehyde (MDA). Timepoint: Before starting medications and at 28 weeks. Method of measurement: TBARS method.

—

Secondary

Measure	Time frame
Lipid profiles of total cholesterol, HDL-C and triglyceride concentrations. Timepoint: Before starting medications and at 28 weeks. Method of measurement: Enzymatic method using Selectra II autoanalyzer.;Inflammatory markers A. Inflammatory factor hs-CRP. Timepoint: Before starting medications and at 28 weeks. Method of measurement: ELISA device (immunoassay method).;Nitric Oxide Inflammatory Marker Nitric Oxide Amount. Timepoint: Before starting medications and at 28 weeks. Method of measurement: The grease reaction is measured.;Fasting blood sugar and insulin resistance. Timepoint: Before starting medications and at 28 weeks. Method of measurement: Glucose oxidase / peroxidase assay using commercially available kits.	—

Measure

Time frame

Lipid profiles of total cholesterol, HDL-C and triglyceride concentrations. Timepoint: Before starting medications and at 28 weeks. Method of measurement: Enzymatic method using Selectra II autoanalyzer.;Inflammatory markers A. Inflammatory factor hs-CRP. Timepoint: Before starting medications and at 28 weeks. Method of measurement: ELISA device (immunoassay method).;Nitric Oxide Inflammatory Marker Nitric Oxide Amount. Timepoint: Before starting medications and at 28 weeks. Method of measurement: The grease reaction is measured.;Fasting blood sugar and insulin resistance. Timepoint: Before starting medications and at 28 weeks. Method of measurement: Glucose oxidase / peroxidase assay using commercially available kits.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSedighe Youosefi

Shiraz University of Medical Sciences

sedighe59yoosefi@gmail.com+98 71 3612 8258

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026